Researchers from Columbia, Mo.-based University of Missouri School of Medicine evaluated this by either removing the AGTR1 gene in mice with acute myeloid leukemia or giving the mice with this cancer the gene-blocking drug Losartan.
Deleting the gene in mice led to “decreased leukemic burden and increased survival,” according to the researchers.
Treating the mice with Losartan was found to enhance “the efficacy of chemotherapy against AML and prevented cardiotoxicity associated with the chemotherapy treatment,” they wrote.
Chemotherapy has long been the only treatment for patients with acute myeloid leukemia, but cardiotoxicity from chemotherapy harms the heart. However, the ability to protect the heart while also fighting the cancer could be used to improve treatment overall and patient outcomes.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
